73 results about "Interleukin l" patented technology

The invention provides human interleukin interleukin-2 (IL-2) / Fc fusion protein. The human IL-2 of the fusion protein comprises all sequences of a human IL-2 extracellular region; the Fc fragments comprise a hinge region, a CH2 region and a CH3 region; the human IL-2 / Fc sequences are fused directly or through a connection sequence; and the Fc fragments are human or animal IgG, IgM, IgD and IgA orsubtypes thereof. The ADCC and CDC effective factor action can be eliminated, and in addition, the human IL-2 / Fc fusion protein has the compatibility with a recombinant IL-2 receptor so that the half-life period is obviously prolonged and also has all the biological activity of the IL-2 receptor. The IL-2 / Fc obviously improves the humoral immune response stimulated by the hepatitis B vaccine and the immunity of the CD8+T cells targeted to the hepatitis B vaccine. Moreover, the balance immune (suppression) of the effective T cells and the regulatory t cells can be adjusted under the action of the cyclosporine A so that the pancreatic islet transplantation immune tolerance is induced.

The invention relates to a detection kit for interleukin 6. The detection kit comprises two specific monoclonal antibodies of the interleukin 6; one monoclonal antibody covering a perforated plate, the other monoclonal antibody labeled by biotin and the interleukin 6 of a sample to be detected form a sandwich compound structure of covering antibody-antigen-biotin labeled antibody; the biotin labeled on the antibody combines with streptavidin labeled by HRP, and then the HRP reacts with a substrate to generate a signal which is used for conducting quantitative analysis on the interleukin 6. The detection kit can quantitatively detect the content of the interleukin 6 in the sample rapidly and sensitively.

The invention discloses a method for effectively culturing tumor infiltrating lymphocytes (TILs). The method comprises the following steps: extracting mononuclear cells from the pectoral ascite or tumor tissue of a patient, washing, inoculating into a culture bottle coated with recombinant human fibrin and cluster-of-differentiation-3 antibody, culturing for 24 hours, adding interleukin II, then using a serum-free culture medium containing the interleukin II and the supernatant pectoral ascite to enlarge and subculture every two or three days, and adding apoptosis-regulated protein survivin and mucoprotein-1 on the twelveth or thirteenth day to activate the killing activity; and harvesting cells on the fourteenth day. By adopting the method, the culture time, which is only 14 days, is greatly shortened, so that the hospital stays of the patient can be greatly shortened and the hospital burden of the patient can be reduced. Meanwhile, the problems that the cell proliferation speed is low and the proliferation ratio is low can be solved, thus the number of the cultured cells can meet the clinical requirement. The cultured TILs has strong cell specificity so as to enhance the clinical curative effect.

The invention discloses a technology in the aspect of immunology, in particular to a method for amplifying natural killer (NK) cells and CD8 lymphocyte by interleukin 2 and interleukin 15 receptor (IgG1 Fc) and interleukin 2 complex. A polypeptide complex is cultured by an interleukin 2 and the interleukin 15 receptor which are protein having the expression function, and the aim of changing the immune state is achieved by the lymphocyte or a lymphocyte precursor cell activated and amplified by the polypeptide complex. The patient is helped to resist a tumour, viruses and bacteria by improving the immunity through the interleukin 15 receptor (IgG1 Fc) and interleukin 2 complex, and the realizing effect is good. The invention has wide prospect in the aspect of immunology.

The invention relates to the field of immunology, in particular to a method for amplifying and activating a natural killer (NK) cell into a lymphokine-activated killer (LAK) cell by using a CD8 alpha-interleukin 21-CD137 compound. The method disclosed by the invention comprises the following steps of: forming the CD8 alpha-interleukin 21-CD137 compound by using CD8 alpha, interleukin 21 and a CD137 functional polypeptide, making an exogenous expression vector enter a host K562 cell, then activating a promoter and culturing a cell to obtain a cell for expressing a transmembrane interleukin 21-CD137 compound; and purifying the compound in the conventional way, and amplifying and activating a lymphocyte by using the purified compound to generate the LAK cell. The method has the advantage that: the LAK cell cultured and amplified by using the transmembrane interleukin 21-CD137 compound and a small dose of interleukin 2 is used for enhancing the immunity of a patient to help the patient resist tumors, viruses and bacteria. The method has a wide clinical using prospect.

The present disclosure is directed to interleukin-10 (IL-10) peptides and isolated antibodies that specifically bind to the IL-10 peptides. The IL-10 peptides and the isolated antibodies may be administered alone or as an animal feed additive to treat gastrointestinal protozoan infection in animals.

The invention relates to an immunogene therapeutic drug for chronic hepatitis B and a preparation method for the immunogene therapeutic drug. The active component of the drug is a replication-competent recombinant vector pSVK-dSFValpha-IRES-hIL-12 (for short, pSVK-HBVE), which is constructed by taking a pSVK carrier as a starting carrier and carries a fusion gene dSFValpha-IRES-hIL12. An antibody targeting interferon alpha and human IL-12 are co-expressed in the replication-competent recombinant vector pSVK to construct a humanized HBsAg dsFv antibody, human interferon-alpha and interleukin-12 fusion expression vector pSVK-dSFValpha-IRES-hIL-12, the fusion expression vector is efficiently expressed in an eukaryotic cell and in vitro, the combined application of human IL-12 and human IFN-alpha has an important synergistic effect during the tumor control process, and a safe and efficient immunogene therapeutic drug is provided for gene therapy of chronic hepatitis B.

Methods and compositions for inhibiting 5-Lipoxygenase, 15-Lipoxygenase, COX-1, COX-2, Interleukin-lβ, Interleukin-6, α, HLE, and iNOS. Methods and compositions for treating and preventing diseases, including inflammatory diseases and skin cancer. Compositions comprising processed Morinda citrifolia components, some of which include leaf extracts, leaf juice, and / or seed extracts.

The γc-family cytokines, Interleukin-2 (IL-2), Interleukin-4 (IL-4), Interleukin-7 (IL-7), Interleukin-9 (IL-9), Interleukin-15 (IL-15), and Interleukin-21 (IL-21), are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. The present embodiments relate to the design of peptide antagonists based on the consensus γc-subunit binding site to inhibit γc-cytokine activity. In several embodiments, peptide antagonists exhibit Simul-Block activity, inhibiting the activity of multiple γc-cytokine family members.

The present disclosure is directed to interleukin-10 (IL-10) peptides and isolated antibodies that specifically bind to the IL-10 peptides. The IL-10 peptides and the isolated antibodies may be administered alone or as an animal feed additive to treat gastrointestinal protozoan infection in animals.

The present invention is directed to compositions and methods for selective induction of apoptosis in cancer cells, particularly malignant cancer cells, by delivery of a IL-1α propiece polypeptide (e.g., a native IL-1α propiece polypeptide, including IL-1α propiece polypeptide variant) to a cancer cell.

The invention relates to a fusion protein prodrug taking interleukin 15 as an active ingredient. The prodrug is a fusion protein and includes the following structural units: (1) a first structural unit is the fragment of one or a subunit of an interleukin 15 (IL15) acceptor; (2) a second structural unit is IL15 having activity; (3) a third structural unit located on the C end of the fusion proteinis an antibody Fc fragment; (4) a connection fragment 1 is used for connecting the first, second and third structural units; (5) a fourth structural unit located on the N end of the fusion protein isthe extracellular fragment of the beta subunit of the IL15 acceptor; and (6) a connection fragment 2 is used for connecting the fourth structural unit and residual structural units.

The invention discloses a method for constructing a CHO cell strain for stably and efficiently expressing a human serum albumin and an interleukin II fusion protein. The CHO monoclonal cell strain for stably and efficiently expressing the human-derived recombinant protein can be obtained by electrically transferring a plasmid with the human serum albumin and the interleukin II fusion gene into the CHO cell. The monoclonal cell strain obtained by the invention is capable of secretory expression of the human serum albumin and the interleukin II fusion protein, the protein expression quantity is high, and the fusion protein can be obtained through the separation and purification; the in vitro biological activities of two fusion proteins are higher than the mol monomer 1L-2 activity. The CHO cell strain can be widely applied to the medicines for treating various diseases such as tumor, hepatitis, pneumonia and immunodeficiency disease.

The invention belongs to the technical field of genetic engineering antibody, and particularly discloses a single-chain antibody C2 of a fully-human anti-human interleukin-21 receptor, and a preparation method and application thereof. The invention also discloses amino acid sequences of immunoglobulin molecules in a heavy chain variable region and a light chain variable region of the C2, including the sequences corresponding to complementarity determining regions CDR1, CDR2 and CDR3. The invention also provides a method for expressing the C2, which comprises the following steps of: screening the single chain antibody C2 of the fully-human anti-human interleukin-21 receptor from a natural human phage antibody library; and obtaining the single chain antibody through secretion and expression of a prokaryotic system, and nickel column affinity chromatography and purification. The single-chain antibody can be specifically bonded to the human interleukin-21 receptor, can inhibit the activation of the interleukin-21 receptor, is applicable to the treatment of interleukin-21 receptor-related diseases including rheumatoid arthritis, autoimmune diseases such as transplantation rejection and other immune system diseases, and also can be coupled with detectable substances and therapeutic agents.

The invention provides a novel recombinant oncolytic adenovirus expressing human interleukin 15. Specifically, the gene promoter of a type 5 adenovirus E1 region is replaced with a transcription factor E2F-1 gene, and an hIL-15 gene is inserted to an E3 region to construct the recombinant oncolytic adenovirus. According to the invention, E2F-1 is used as the promoter to realize replication of virus specificity in tumor cells, and at the same time, loading of human IL-15 gene in a virogene E3 region can further enhance the anti-tumor effect of the virus. As the pRb / E2F pathway defects exist extensively in solid tumors, through the tumor resolving effect of the virus, a variety of tumor antigens from the individual itself can be acquired, and are not limited by antigen subcellular localization, thus being conducive to producing anti-tumor immune response with self tumor specificity, and having individualized and general treatment significance. In addition, the virus replication process drives the IL-15 gene expression, high concentration IL-15 can be obtained from a part of the virus-infected tumor cell, thereby being in favor of stimulating the activity of immune cells, activating the general immune response and strengthening the antitumor effect.

The present invention provides an interleukin 17A (IL-17A)-targeting antibody, a preparation method and applications thereof, particularly a new anti-IL-17A monoclonal antibody. According to the present invention, the antibody can bind to IL-17A antigen in a high-specificity manner, has high affinity and low immunogenicity, and is used for preparing drugs for prevention or treatment of IL-17A related diseases such as various inflammations or autoimmune diseases.

The invention relates to a method for detecting anti-inflammatory activity of a rhododendron molle extractive and application thereof. The method comprises the steps that a preparation method of the rhododendron molle extractive is established, a rhododendron molle extractive anti-inflammatory activity cell detection model is constructed, and an analysis method of the rhododendron molle extractivefor inhibiting inflammatory factors and related gene expression in inflammatory cells is established. The method for detecting the anti-inflammatory activity of the rhododendron molle extractive andthe application thereof have the advantages that results show that a rhododendron molle blade methanol extractive has stronger anti-inflammatory activity, can significantly inhibit secretion of nitricoxide (NO), tumor necrosis factor-alpha (TNF-alpha), interleukin 1beta (IL-1belta) and other inflammatory factors in RAW264.7 cells stimulated by lipopolysaccharide (LPS) and gene expression thereof,and also significantly inhibit the expression of two key enzyme genes of iNOS and COX-2 in relevant paths of inflammation.

The invention provides medicine for treating asthma. The medicine is glycoprotein, mixture of polysaccharide and protein, polypeptide or protein. The medicine has the advantages that the bronchial hyperresponsiveness of a mouse asthma model can be effectively lowered, the tracheospasm can be relieved, and airway pressure-time index (APTI) is 726-880 per second centimeter water column; the inflammation in the lung can be treated effectively, inflammatory cell infiltration can be reduced, and the percentage of eosinophilic granulocyte is 14.6-16.6%; the gamma-interferon (IFN-gamma) and antibody which are capable of inhibiting asthmatic attack can be increased, and the contents of interleukin-4 (IL-4), interleukin-5 (IL-5) and interleukin-13 (IL-13) which can induce the asthma can be lowered; the medicine is safe, efficient, free of side effect, quick in action during asthma preventing and treatment, capable of relieving chest distress and short of breath and evident in curative effect on the asthma.

The invention discloses an interleukin-4 therapeutic vaccine for treating immune related diseases of humans or animals. The interleukin-4 therapeutic vaccine is a protein vaccine or coupling protein vaccine of any form prepared by taking the natural or artificially synthesized complete protein or protein fragment of interleukin-4 as an antigen; or the interleukin-4 therapeutic vaccine is a gene vaccine or fusion gene vaccine of any form prepared by taking the complete gene or gene fragment of interleukin-4 as the antigen gene or the major antigen gene. The IL (interleukin)-4 vaccine is used for performing active immunotherapy on a host, generally, the effective time lasts for about 2-3 months by immunization for the first time, the effective therapeutic time lasts for about half a year by secondary immunization, and recovery can be achieved by 1-3 times of immunotherapy. Compared with direct application of anti-IL-4 antibody for treatment, the invention has the characteristics of few times of application, low dose and the like, thereby greatly reducing the therapeutic cost, and also greatly reducing the possibility of generating allergic reaction.

The invention relates to a pharmaceutical composition for local modulation of T cell and B cell responses at the site of allergen or antigen presentation, made of one or more preparations comprising one or more antigens or allergens, and a therapeutically effective dose of two or more low molecular weight immune modulators selected from four groups of tolerance-inducing therapeutics comprising inhibitors of complement-mediated functions, inhibitors of tumor necrosis factor receptor 1 (TNFR1)-mediated functions, inhibitors of interleukin 4- and interleukin 13-mediated functions, and therapeutic agents suitable for vitamin D3 supplementation wherein preferably two or more low molecular weight immune modulators and one or more antigens or allergens are coated or adsorbed on or embedded in a matrix, wherein the matrix is selected as to enable sustained release of one or more antigens or allergens and two or more immune modulators for the treatment of T cell-mediated diseases.

The invention discloses recombinant mesenchymal stem cells, a preparation method and application thereof. A first messenger RNA (ribonucleic acid) for expressing P lectin glycoprotein ligand-1, a second messenger RNA for expressing sialated Lewis oligosaccharide-X antigen and a third messenger RNA for expressing interleukin-10 are transfected into mesenchymal stem cells to obtain the recombinant mesenchymal stem cells.

The invention discloses a recombinant rabies virus rHEP-CaIL6 carrying an immune enhancement factor interleukin (IL) 6 gene and application thereof. The recombinant virus takes rabies virus HEP-Flury strain as the skeleton, the IL6 gene of canine is inserted to a position between the G and L gene of HEP-Flury to obtain a recombinant plasmid pHEP-CaIL6, and finally saving screening is carried out to obtain the recombinant rabies virus strain rHEP-CaIL6. The recombinant virus carries the immune enhancement factor, can enhance the immune response and induce the production of higher rabies virus neutralizing antibody, thus better protecting the body from resisting the attack of lethal rabies virus, also can produce a neutralizing antibody with protective ability at a low dose, and lowers the cost of canine vaccines. Moreover, the IL6 gene is recombined into the rabies virus, thus achieving stable expression of IL6 protein, also avoiding the overexpression thereof, and overcoming the defect that excessive IL6 can cause pathological injury.

The invention relates to a DC-based glioma holoantigen vaccine and a preparation method thereof. The preparation method includes the steps of 1), acquiring immature DCs; 2), adding in glioma holoantigen and then co-culturing the glioma holoantigen with the immature DCs; and 3), adding in tumor necrosis factor-alpha and interleukin or lipopolysaccharide to continuously culture for 10-24 hours until DCs are matured and loaded with the glioma holoantigen. The DC-based glioma holoantigen vaccine carries complete antigenic information and is high in immunogenicity and specificity and capable of effectively regulating body immune mechanisms for gliomas.

The invention discloses chicken interleukin-10 (ChIL-10) monoclonal antibodies and a preparation method and application thereof. The preparation method comprises the following steps: taking prokaryotically expressed recombinant protein ChIL-10 as an immunogen and eukaryotic cell line-expressed ChIL-10 protein as a screening antigen, carrying out cell fusion, and screening hybridoma cells by an IFA (incomplete Freund's adjuvant) to obtain three cell strains for secreting the chicken interleukin-10 monoclonal antibodies, wherein the monoclonal antibodies secreted by the hybridoma cell strains 2F6 are highest in in titer, stability and specificity, and have a microbiological collection number of CGMCC (China General Microbiological Culture Collection Center) NO.7657. The invention further provides the application of the hybridoma cell strains 2F6 and the monoclonal antibodies secreted by the hybridoma cell strains 2F6 to detection or purification of the chicken interleukin-10 protein.

The present invention provides means and methods for treating Interleukin 18 (IL-18)-associated diseases and disorders, in particular, the present invention discloses antibodies specific for free IL-18 and IL-18 Binding Protein (IL-18BP) for use in such treatments and for the diagnosis of the diseases and disorders.

The invention belongs to the field of cytobiology and particularly relates to a culture medium and method for culturing DCs. The culture medium for culturing the DCs comprises a first component, a second component and a third component. The first component is an RPMI1640 culture medium containing bovine serum albumin, interleukin 4, GM-CSF and stem cell factors (SCF). The second component is an RPMI1640 culture medium containing bovine serum albumin, interleukin 14, interleukin 2, interleukin 4 and GM-CSF. The third component is an RPMI1640 culture medium containing bovine serum albumin, CD40L, GM-CSF and interleukin 4. The result shows that the antigen presentation capacity of the DCs cultured by the culture medium is higher, the sensitization capacity to T cells is higher, and the killing capacity to tumors is greatly improved. Use of serum is avoided, and the risk of pathogenic microorganisms is relieved.

The invention discloses a mesenchymal stem cell capable of inhibiting Th17 cell activation. The mesenchymal stem cell can specifically express human interleukin 23 acceptor homolog through a gene modifying method, so that combination between IL-23 and an IL-23 acceptor is competitively inhibited. Therefore, the mesenchymal stem cell can be applied to inhibiting correlated signal channels and inflammation reaction of IL-23 mediated inflammation. The invention further discloses the human interleukin 23 acceptor homolog as well as a preparation method and application of the mesenchymal stem cell.

The invention discloses chicken interleukin-10 (ChIL-10) monoclonal antibodies and a preparation method and application thereof. The preparation method comprises the following steps: taking prokaryotically expressed recombinant protein ChIL-10 as an immunogen and eukaryotic cell line-expressed ChIL-10 protein as a screening antigen, carrying out cell fusion, and screening hybridoma cells by an IFA (incomplete Freund's adjuvant) to obtain three cell strains for secreting the chicken interleukin-10 monoclonal antibodies, wherein the monoclonal antibodies secreted by the hybridoma cell strains 2F6 are highest in in titer, stability and specificity, and have a microbiological collection number of CGMCC (China General Microbiological Culture Collection Center) NO.7657. The invention further provides the application of the hybridoma cell strains 2F6 and the monoclonal antibodies secreted by the hybridoma cell strains 2F6 to detection or purification of the chicken interleukin-10 protein.